Chimeric antigen receptor (CAR) T cell therapy, which uses a patient’s own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have struggled to adapt the treatment for solid tumors—including prostate, breast, lung and ovarian cancer—which make up about 90% of all cancer cases.
This article was originally published on MedicalXpress.com